Inhibitors of PIM-1 Signaling Pathways as Anticancer Agents: Pharmacological and Structural Viewpoints.

Authors

Banty Kumar, Ankur Vaidya, Shweta Jain, Sanjeev Kumar Sahu, Preeti Patel, Vivek Asati

Published in

ChemMedChem. Volume 21. Issue 20. Pages e70533. Oct 28, 2026.

Abstract

Pim-1, a carcinogenic threonine and serine kinase, inhibits apoptosis and advances the cell cycle. It is overexpressed in several human cancers. The proviral integration site of Moloney murine leukemia virus 1 is Pim-1. Previous studies have shown that the Pim-1 30-UTR regulates the stability of Pim-1 mRNA. Threonine and serine are identified as the proto-oncogene Pim-1 kinase. Pim-1 mediates numerous biological processes, including apoptosis, cell division, proliferation, and cancer. Pim-1-mediated anticancer activity has been reported in several analogs of thiazole/bis-thiazole, tetrazine, thiophenes, quinoline, pyrazolopyrimidine, 3-cyanopyridine, thiazolidine-2,4-dione, thieno[2,3-b]pyridine, triazolo[4,3-b]pyridazine, pyrazolo[1,5-a]pyrimidines, and pyrazolo[3,4-b]pyridine derivatives. Additionally, flavonoids and amino alcohol compounds that constitute Pim-1-mediated cancer therapy have also been identified thus far. Many compounds with Pim-1-mediated cytotoxicity have been discovered up to this point, and scientists are currently concentrating on bringing novel compounds with anticancer potential to the market.

PMID:
42875387
Bibliographic data and abstract were imported from PubMed on 15 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.